Back

Three-year safety and effectiveness of Hybrid Ablation versus Catheter Ablation: Final results of the CEASE-AF trial

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Catheter ablation procedural outcome Rhythm Control, Hybrid Therapy EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Professor Piotr Suwalski

National Institute of Medicine of the Ministry of Interior and Administration, Warsaw (Poland)

5 More presentations in this session

Presentation thumbnail
Evaluation of effectiveness and outcomes of pulsed field ablation of atrial fibrillation in patients with obesity
Doctor S. Aminolsharieh Najafi (Frankfurt am Main, DE)
Abstract Slides Video
Presentation thumbnail
Pulsed filed ablation: comparison of procedural data and re-do data for the 31mm and 35mm device
Doctor L. Urbanek (Frankfurt, DE)
Abstract Slides Video
Presentation thumbnail
Impact of alternative efficacy endpoint definitions on reported outcomes after ablation of paroxysmal atrial fibrillation, insights from the COMPARE CRYO study using continuous rhythm monitoring
Doctor S. Iqbal (Bern, CH)
Abstract Slides Video
Presentation thumbnail
1 year clinical & safety outcome of obese patients undergoing PVI for atrial fibrillation with pulsed field or cryoballoon ablation - a prospensity matched analysis
Doctor S. Feickert (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Pulmonary vein reconnections at time of repeat procedure, variations by ablation modality.
Doctor K. Qazalbash (Dublin, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Catheter ablation procedural outcome
Video

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Two-year safety and effectiveness of hybrid ablation versus catheter ablation in patients with non-paroxysmal AF: mid-term results of the CEASE-AF trial
thumbnail
Congress Presentation
The hybrid approach
thumbnail
Congress Presentation
Hybrid ablation versus repeated catheter ablation in persistent atrial fibrillation: long-term results of the HARTCAP-AF trial.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources